Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or ...

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and ...

Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Scholar Rock in a ...

On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock(NASDAQ:SRRK) in an open market transaction. How does the transaction compare to previous insider ...

Strategic collaborations and late-stage clinical assets position Scholar Rock to compete in high-value therapeutic markets. Foolish take Scholar Rock is a clinical-stage biotech.

Review the current Scholar Rock Holding Corp (SRRK:XNAS) dividend yield and history to decide if SRRK is the best investment for you.

Queen's legendary guitarist, Brian May, known for iconic solos, also holds a PhD in astrophysics. His thesis, completed in ...